Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid

Skin Res Technol. 2023 Oct;29(10):e13488. doi: 10.1111/srt.13488.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Pemphigoid, Bullous* / drug therapy

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized